RxDoctor Payments Data

Farshid Mirzaee, MD

Urology · Rancho Mirage, CANPI 1194969436

Payments from drug & device makers

$5,317in general payments, 2019–2025

Across 102 payments — averaging $52.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Palette Life Sciences, Inc.$1K
  • Boston Scientific$1K
  • Abbott$502
  • Teleflex LLC$480
  • Rochester Medical Corporation$218
  • Intuitive Surgical$171
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$81915%
  • Food & beverage$4,49885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,317 in reported general payments places this provider in the 60th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$286,884
Medicare patients
793
Services billed
4,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron75$43,075
GemtesaVibegron19$14,725
Tamsulosin Hcl520$8,048
Testosterone32$7,702
Finasteride360$5,101
Mirabegron ErMirabegron11$4,706
Testosterone Cypionate62$1,920
Oxybutynin Chloride ErOxybutynin Chloride84$1,902
Methenamine Hippurate22$1,501
Potassium Citrate ErPotassium Citrate13$1,414
Ciprofloxacin Hcl275$1,044
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen119$831
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$763
Alfuzosin Hcl ErAlfuzosin Hcl41$742
Bicalutamide15$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$168$43,07575 claims
Sumitomo Pharma America, Inc.Gemtesa$42$14,72519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,324 urology providers in California.

Other urology in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →